The following presentations are available to be viewed up to 1 week after the Biotech and Money London conference.

The individuals associated with each presentation will be present and can be contacted to arrange 1-2-1 meetings at the Biotech and Money London congress.

If you are an attending delegate, login to Meeting Mojo using the link below, along with your email address and your password to set up onsite meetings directly:



Lipotype - Innovative Lipidomics Technology for Biomarker Identification and Precision Medicine

Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale.

Lipotype is a spin-off company from the Kai Simons and Andrej Shevchenko labs of the world-renowned Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Lipotype offers high quality lipid analysis services for a wide range of customers and applications including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, as well as for the small-scale profiling needs of academic researchers.
Oliver Uecke, Head of Business Development, Lipotype

View PDF Presentation

MRC Technology - Do you have early stage ‘parked’ assets in therapeutics or diagnostics?

MRC Technology is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere.

As a champion for human health, MRC Technology partners with academic, biotechnology, pharmaceutical, and charity organisations to move promising medical research forward into viable and accessible patient treatments. (46 words)

Tags: Drug Discovery; Antibodies; Medicinal Chemistry; Collaboration

Andrew Mercieca, Director of Finance, MRCT

View Powerpoint Presentation

MSI Ltd. - Mitochondrial Substrate Invention Ltd. 

Dr Larisa Andreeva, Director / Co-inventor, MSI Ltd.

View PDF Presentation

Poiesis Therapeutics - Innovative Healthcare for Pets

Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics, diagnostics and research tools from human biomedical research and then developing them to address unmet needs in the veterinary market for companion animals – horses, dogs and cats.

Jessica Dugan, President and CEO, Poiesis Therapeutics

View PDF Presentation

Pluristem Therapeutics - Placental Cell Therapies - Advancing Cell Therapeutic Products for Clinical Use

Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena.

Zami Aberman, President and CEO, Pluristem

View Powerpoint Presentation

Re-Pharm – Using Smart Reprofiling to identify valuable new uses for old molecules

Re-Pharm is a clinical-stage company focussed on the development of new therapeutics through re-profiling of existing, marketed compounds. The company has developed a re-profiling platform; through which we have identified a series of commercially interesting opportunities. Our lead asset RP0217 was identified in this way and has completed pre-clinical development in a variety of topical anti-inflammatory indications. The company is looking to raise a finance round to complete first-in-man studies on RP0217 and to build out the pipeline of other repositioned assets.

Tags – Re-profiling, computational chemistry, anti-inflammatory, ophthalmic, respiratory.

View Audio Assisted Powerpoint Presentation (please enable sound to hear CEO commentary)

SEEK Group - Funding opportunities in influenza and cancer

Post proof of principle assets focused into new investment opportunity and vehicles for next stage growth

SEEK Group,  headquartered in London,  is involved in research and development, sales of over the counter and prescription medicines and management and operation of clinics. It undertakes all these activities in order to bring safe, effective and low costs medicines to patients in the shortest time possible to radically improve human health in major disease areas.

Tags. Vaccine, Universal influenza, HIV, cancer drug, phase II licensing, opportunity, collaboration.

View Powerpoint Presentation

Tonix Pharma - Late stage clinical development programs in pain and psychiatry

Tonix is a NASDAQ-listed pharmaceutical company with three experimental small molecule prescription medicines in late stage clinical development.  This year Tonix will report results from: the Phase 3 fibromyalgia study (Q3); the registration quality Phase 2 study in PTSD (Q2); and the Phase 2 episodic tension-type headache study (Q1).

Tags: Pain, FM, PTSD, Headache

Marlis Dunne, Manager Ireland, Tonix Pharma Limited

View PDF Presentation

Vasgen - Innovative ocular and cancer therapeutics

Vasgen Ltd is an early-stage biotech company based in London UK developing novel monoclonal antibody therapeutics for unmet clinical needs in ophthalmology and cancer medicine. The company is developing a breakthrough antibody platform (AbIMP®) that generates selective inhibitors of therapeutically important but previously intractable metzincin protease targets.

Salman Rahman, CEO, Vasgen

View PDF Presentation